IGF1 and acromegaly: The data of our cohort support a protective role of the GHR polymorphisms, also independently of the reaching of biochemical control of acromegaly, and independently from the final IGF-I levels, supporting the hypothesis that the interaction of GHR polymorphism and treatment modality in fracture risk is independent of treatment outcome, as reported in Figure 1.